A new patch Ambulatory ECG monitoring company called WearLing has announced that it has acquired the Independent Diagnostic Testing Facility (IDTF) laboratory called AMI Cardiac Monitoring LLC.
AMI Cardiac Monitoring is an established ECG Laboratory for ambulatory cardiac (AECG) monitoring services. The aquisition will serve to delivery diagnostic ECG services across the USA. WearLinq offers their unique eWave wearable AECG patch which is a 6 – lead which has recently recieved their FDA 510k market clearance in the USA.
The acquistion is marked at an initial close of $6.7 million start-up capital investment from various firms such as SpringTide, Amino Capital & others.
The press release continues to note that 1 out of 3 people in the US will develop Atrial Fibrillation at some point in their lifetime. Cardiac Specialist know that Atrial Fibrillation increased the risk for stroke by nearly 5x which has been noted in various published clinical studies. A-Fib is often asymptomatic where the patient does not feel or notice any symptom that A Fib exists therefore many patients can remain undiagnosed.
The WearLinq eWave represents a big step in ambulatory cardiac monitoring as the provides cardiologists with a detailed 6-lead ECG multi-vector view of the patients ECG with clear P-wave distinction. The eWave patch monitor communicates with a patient’s cellular phone to report symptoms.
The WearLinq eWave AECG device is designed to be a slim wearable patch adhesive monitor to maximize patient compliance enabling patients to maintain their lifestyle while continuously monitoring their ECG. The eWave is integrated with the WearLinq cloud platform to ensure near-real time analysis & alerts.
References:
- https://www.businesswire.com/news/home/20240521325743/en/
- www.amicardiac.com
- www.wearlinq.com
